secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001104659-24-064825
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports 65% ORR, 30% complete response rate for lifileucel + pembro in frontline melanoma
--------------------------------------------------------------------------------

- Confirmed ORR of 65.2% (30.4% CR, 34.8% PR) in 23 evaluable frontline advanced melanoma patients.
- Median follow-up 21.7 months; nearly all responses ongoing; 53.3% of responders had duration ≥12 months.
- All evaluable patients showed target lesion regression; safety consistent with known profiles of pembrolizumab, lymphodepletion, IL-2.
- Data supports Phase 3 TILVANCE-301 trial with dual-primary endpoints ORR and PFS; interim ORR analysis may support accelerated approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924064825/0001104659-24-064825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924064825/tm2415493d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-064825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer